Edition:
United States

Axsome Therapeutics Inc (AXSM.OQ)

AXSM.OQ on NASDAQ Stock Exchange Global Market

2.70USD
16 Feb 2018
Change (% chg)

$0.10 (+3.85%)
Prev Close
$2.60
Open
$2.60
Day's High
$2.70
Day's Low
$2.60
Volume
64,441
Avg. Vol
50,855
52-wk High
$6.45
52-wk Low
$2.47

Chart for

About

Axsome Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in developing therapies for the management of central nervous system (CNS) disorders, including pain. It operates in the business of developing novel therapies for the management of CNS disorders segment. Its product candidate, AXS-02... (more)

Overall

Beta: --
Market Cap(Mil.): $68.71
Shares Outstanding(Mil.): 25.45
Dividend: --
Yield (%): --

Financials

  Industry Sector
P/E (TTM): -- 178.11 17.27
EPS (TTM): -- -- --
ROI: -- -1.15 35.43
ROE: -- -20.84 17.10

BRIEF-Axsome Therapeutics Says AXS-02 Independent Data Monitoring Committee Recommends Continuation Of COAST-1 Trial

* AXSOME THERAPEUTICS ANNOUNCES AXS-02 INDEPENDENT DATA MONITORING COMMITTEE RECOMMENDS CONTINUATION OF COAST-1 TRIAL AND DISCONTINUATION OF CREATE-1 TRIAL

Jan 09 2018

BRIEF-Sabby Management Reports A 5.52 Percent Passive Stake In Axsome Therapeutics

* SABBY MANAGEMENT, LLC REPORTS A 5.52 PERCENT PASSIVE STAKE IN AXSOME THERAPEUTICS INC AS OF DEC 1 - SEC FILING Source text : [http://bit.ly/2jNkBHB] Further company coverage:

Dec 04 2017

BRIEF-Axsome Therapeutics Announces AXS-07 For The Treatment Of Migraine

* AXSOME THERAPEUTICS ANNOUNCES AXS-07 FOR THE TREATMENT OF MIGRAINE

Nov 28 2017

BRIEF-Axsome Therapeutics reports Q3 loss per share $0.27

* Axsome Therapeutics reports third quarter 2017 financial results

Nov 08 2017

BRIEF-Axsome enters agreement to sell up to $30 mln of shares of co's common stock

* Axsome Therapeutics-entered sales agreement to sell through leerink up to $30 million of shares of co's common stock,par value $0.0001/share-SEC filing Source text : (http://bit.ly/2gxqvzm) Further company coverage:

Oct 20 2017

Earnings vs. Estimates